Download Citation
Article Source:
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao W,
Wang TY,
Riely GJ,
Miller VA,
Pan Q,
et al.
(2005)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib.
PLOS Medicine 2(1): e17.
https://doi.org/10.1371/journal.pmed.0020017